<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02772679</url>
  </required_header>
  <id_info>
    <org_study_id>16-19632</org_study_id>
    <nct_id>NCT02772679</nct_id>
  </id_info>
  <brief_title>T1DM Immunotherapy Using Polyclonal Tregs + IL-2</brief_title>
  <acronym>TILT</acronym>
  <official_title>A Phase 1 Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy With Interleukin-2 for the Treatment of Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey Bluestone</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety of Tregs + IL-2 and survival of Tregs in
      patients with recent onset T1DM who receive infusions of autologous Tregs + IL-2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that ex vivo expanded human autologous CD4+CD127lo/-CD25+
      polyclonal regulatory T cells (Polyclonal Tregs) plus Interleukin-2 (IL-2) administered to
      patients with Type 1 Diabetes Mellitus (T1DM) will be safe and biologically active. A Phase I
      trial with this cellular therapy plus IL-2 will lead the way for Phase II trials that test
      for efficacy based on preservation of C-peptide, reduced exogenous insulin requirements and
      improved glycemic control.

      This is a Phase I safety/dosing study of Polyclonal Tregs + IL-2 in patients with T1DM.

      The Tregs will be expanded using an established protocol utilizing anti-CD3/anti-CD28 beads
      plus IL-2. The study will involve 2 dosing cohorts of 6-8 T1DM patients each. The primary
      objective of this study is to assess the safety of Tregs + IL-2 and survival of Tregs in
      patients with recent onset T1DM who receive infusions of autologous Tregs + IL-2. The study
      will also assess potential effects of Tregs on beta cell function and the autoimmune
      response.

      Subjects will receive Polyclonal Tregs at doses of 3 or 20x10^6 cells/kg. The dose of Tregs
      is selected based on a combination of considerations of manufacturing capacity, a predicted
      efficacious dose, and the available safety data of the Treg product currently in clinical
      trials. The IL-2 dose will be 1 x10^6 IU subcutaneously, given daily for 5 consecutive days
      at the completion of the cell infusion and again after 1 month. This dose is based on recent
      studies from Klatzmann et al. in T1DM, where the dose was found to be effective in a
      selective Treg expansion, well tolerated, and without an acute decline in beta cell function
      (Rosenzwajg et al., 2015).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Adverse events of special interest: including infections, malignancies, safety of Treg infusions, and local and systemic reactions to IL-2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival of Tregs</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Comparison of the survival of graded doses of Tregs and IL-2. Calculating the half-life of infused deuterium-labeled Tregs in peripheral circulation will be used to assess the survival of Tregs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-peptide response</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Change in beta cell function over time, as assessed by change in C-peptide area under curve in response to serial mixed meal tolerance tests. Analysis will include a comparison to recent data available from TrialNet placebo treated subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin use</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Insulin use in units per kilogram body weight per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c levels</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe hypoglycemic events</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Severe hypoglycemic events as defined by the inability to selftreat and/or the requirement for glucagon injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve at least a 13-week reduction in insulin dose to &lt; 0.5 units/kg in each treatment arm</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the effects of IL-2 on Treg kinetics and phenotype</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of unmethylated insulin DNA (assay of beta cell death)</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of autoantibodies, enumeration and phenotypes islet antigen tetramer+ CD8, intracellular cytokine staining of T cells, serum proteomics, cytokines, and Treg phenotyping and functional assays</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of general immune response as assessed by, for example, viral tetramer+ CD8 cells and effects of Treg infusions on peripheral blood cells measured by flow cytometry including T cell subsets, B cells and other innate cell subsets</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>PolyTregs+IL-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with type 1 diabetes mellitus will receive ex vivo expanded human autologous polyclonal regulatory T cells plus IL-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PolyTregs+IL-2</intervention_name>
    <description>PolyTregs will be infused into the patient in a single infusion. The first cohort will receive 3 x10^6 cells. The second cohort will receive 20x10^6 cells. Following the day 0 infusion of polyclonal Tregs, subjects will receive two 5-day courses of IL-2 (1 x 106 IU daily), the first on days 3-7 and the second on days 38-42. Administration of the second course of IL-2 may be delayed or withheld depending on threshold criteria for peripheral blood Treg frequencies and MMTT-stimulated C-peptide levels determined on day 28.</description>
    <arm_group_label>PolyTregs+IL-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of T1DM within &gt;3 and &lt;24 months of day 0 according to the American Diabetes
             Association standard criteria.

          2. 18 to 45 years of age on day of screening visit.

          3. Positive for at least one islet cell autoantibody (glutamate decarboxylase; insulin,
             if obtained within 10 days of the onset of insulin therapy; ICA 512-antibody; and/or
             ZnT8).

          4. Peak stimulated C-peptide level &gt;0.2 pmol/mL (0.6 ng/ml) following an MMTT.

          5. Weight of &gt;= 40 kg and &lt;=90.7kg

          6. Adequate venous access to support a blood draw of 5 mls/kg up to maximum of 400 ml
             whole blood and later infusion of investigational therapy

        Exclusion Criteria:

          1. Hemoglobin &lt;10.0 g/dL; leukocytes &lt;3,000/μL; neutrophils &lt;1,500/μL; lymphocytes
             &lt;800μL; platelets &lt;100,000/μL

          2. Any sign of significant chronic active infection (e.g., hepatitis, tuberculosis, EBV,
             or CMV), or screening laboratory evidence consistent with a significant chronic active
             infection (such as positive for HIV, PPD, or HBsAg).

          3. Anticipated ongoing use of diabetes medications other than insulin that affect glucose
             homeostasis, such as metformin, sulfonylureas, thiazolidinediones, glucagon-like
             peptide 1 (GLP-1) mimetics, dipeptidyl peptidase IV (DPP-IV) inhibitors, SGLT2
             inhibitors, or amylin.

          4. Chronic use of systemic glucocorticoids or other immunosuppressive agents, or biologic
             immunomodulators within 6 months prior to study entry. Specifically, subjects who have
             received over 7 days of treatment with 7.5 mg of prednisone (or the equivalent) within
             6 months prior to study entry will be excluded.

          5. History of malignancy (including squamous cell carcinoma of the skin or cervix) except
             adequately treated basal cell carcinoma

          6. Pregnant or breastfeeding women, or any female who is unwilling to use a reliable and
             effective form of contraception for 1 year after Treg +/- IL-2 dosing, and any male
             who is unwilling to use a reliable and effective form of contraception for 3 months
             after Treg +/- IL-2 dosing

          7. Any condition that, in the investigator's opinion, may compromise study participation
             or may confound the interpretation of the study results.

          8. Patients who are unwilling to agree to not participate in another clinical trial,
             which in the opinion of the investigator may confound the results of this study, for
             at least 1 year following Treg infusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jingying Xu, Ph.D.</last_name>
    <email>TILT@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>844-814-8273</phone>
      <email>clinicalresearch@diabetes.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen E Gitelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Ryall, RN</last_name>
      <phone>203-737-4510</phone>
      <email>linda.ryall@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Kevan Herold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol. 2007 Aug;7(8):622-32. Epub 2007 Jul 20. Review.</citation>
    <PMID>17641665</PMID>
  </reference>
  <reference>
    <citation>Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood. 2006 Mar 15;107(6):2409-14. Epub 2005 Nov 22.</citation>
    <PMID>16304057</PMID>
  </reference>
  <reference>
    <citation>Ash S, Yarkoni S, Askenasy N. Lymphopenia is detrimental to therapeutic approaches to type 1 diabetes using regulatory T cells. Immunol Res. 2014 Jan;58(1):101-5. doi: 10.1007/s12026-013-8476-x. Review.</citation>
    <PMID>24371009</PMID>
  </reference>
  <reference>
    <citation>Atkins MB. Interleukin-2: clinical applications. Semin Oncol. 2002 Jun;29(3 Suppl 7):12-7. Review.</citation>
    <PMID>12068383</PMID>
  </reference>
  <reference>
    <citation>Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X, Anthony B, Rosenthal W, Luche H, Fehling HJ, Bluestone JA. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity. 2013 Nov 14;39(5):949-62. doi: 10.1016/j.immuni.2013.10.016.</citation>
    <PMID>24238343</PMID>
  </reference>
  <reference>
    <citation>Bayer AL, Pugliese A, Malek TR. The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation. Immunol Res. 2013 Dec;57(1-3):197-209. doi: 10.1007/s12026-013-8452-5. Review.</citation>
    <PMID>24214027</PMID>
  </reference>
  <reference>
    <citation>Bluestone JA. Regulatory T-cell therapy: is it ready for the clinic? Nat Rev Immunol. 2005 Apr;5(4):343-9. doi: 10.1038/nri1574. Review.</citation>
    <PMID>15775994</PMID>
  </reference>
  <reference>
    <citation>Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010 Dec;10(12):849-59. doi: 10.1038/nri2889. Review.</citation>
    <PMID>21107346</PMID>
  </reference>
  <reference>
    <citation>Castela E, Le Duff F, Butori C, Ticchioni M, Hofman P, Bahadoran P, Lacour JP, Passeron T. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014 Jul;150(7):748-51. doi: 10.1001/jamadermatol.2014.504.</citation>
    <PMID>24872229</PMID>
  </reference>
  <reference>
    <citation>Churlaud G, Jimenez V, Ruberte J, Amadoudji Zin M, Fourcade G, Gottrand G, Casana E, Lambrecht B, Bellier B, Piaggio E, Bosch F, Klatzmann D. Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer. Clin Immunol. 2014 Apr;151(2):114-26. doi: 10.1016/j.clim.2014.02.003. Epub 2014 Feb 19.</citation>
    <PMID>24576619</PMID>
  </reference>
  <reference>
    <citation>Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, Madeira MI, Malmegrim KC, Foss-Freitas MC, Simões BP, Martinez EZ, Foss MC, Burt RK, Voltarelli JC. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009 Apr 15;301(15):1573-9. doi: 10.1001/jama.2009.470.</citation>
    <PMID>19366777</PMID>
  </reference>
  <reference>
    <citation>Diaz-de-Durana Y, Lau J, Knee D, Filippi C, Londei M, McNamara P, Nasoff M, DiDonato M, Glynne R, Herman AE. IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes. PLoS One. 2013 Oct 24;8(10):e78483. doi: 10.1371/journal.pone.0078483. eCollection 2013.</citation>
    <PMID>24205242</PMID>
  </reference>
  <reference>
    <citation>Dirice E, Kahraman S, Jiang W, El Ouaamari A, De Jesus DF, Teo AK, Hu J, Kawamori D, Gaglia JL, Mathis D, Kulkarni RN. Soluble factors secreted by T cells promote β-cell proliferation. Diabetes. 2014 Jan;63(1):188-202. doi: 10.2337/db13-0204. Epub 2013 Oct 2.</citation>
    <PMID>24089508</PMID>
  </reference>
  <reference>
    <citation>Garg G, Tyler JR, Yang JH, Cutler AJ, Downes K, Pekalski M, Bell GL, Nutland S, Peakman M, Todd JA, Wicker LS, Tree TI. Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J Immunol. 2012 May 1;188(9):4644-53. doi: 10.4049/jimmunol.1100272. Epub 2012 Mar 28.</citation>
    <PMID>22461703</PMID>
  </reference>
  <reference>
    <citation>Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, Cagnard N, Carpentier W, Tang Q, Bluestone J, Chatenoud L, Klatzmann D, Salomon BL, Piaggio E. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med. 2010 Aug 30;207(9):1871-8. doi: 10.1084/jem.20100209. Epub 2010 Aug 2.</citation>
    <PMID>20679400</PMID>
  </reference>
  <reference>
    <citation>Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013 Dec;1(4):295-305. doi: 10.1016/S2213-8587(13)70113-X. Epub 2013 Oct 8.</citation>
    <PMID>24622415</PMID>
  </reference>
  <reference>
    <citation>Johnson MC, Garland AL, Nicolson SC, Li C, Samulski RJ, Wang B, Tisch R. β-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice. Diabetes. 2013 Nov;62(11):3775-84. doi: 10.2337/db13-0669. Epub 2013 Jul 24.</citation>
    <PMID>23884888</PMID>
  </reference>
  <reference>
    <citation>Liu R, Zhou Q, La Cava A, Campagnolo DI, Van Kaer L, Shi FD. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur J Immunol. 2010 Jun;40(6):1577-89. doi: 10.1002/eji.200939792.</citation>
    <PMID>20352624</PMID>
  </reference>
  <reference>
    <citation>Macallan DC, Asquith B, Zhang Y, de Lara C, Ghattas H, Defoiche J, Beverley PC. Measurement of proliferation and disappearance of rapid turnover cell populations in human studies using deuterium-labeled glucose. Nat Protoc. 2009;4(9):1313-27. doi: 10.1038/nprot.2009.117. Epub 2009 Aug 20.</citation>
    <PMID>19696750</PMID>
  </reference>
  <reference>
    <citation>Malek TR, Pugliese A. Low-dose IL-2 as a therapeutic agent for tolerance induction. Immunotherapy. 2011 Nov;3(11):1281-4. doi: 10.2217/imt.11.120.</citation>
    <PMID>22053878</PMID>
  </reference>
  <reference>
    <citation>Marek-Trzonkowska N, Myśliwiec M, Dobyszuk A, Grabowska M, Derkowska I, Juścińska J, Owczuk R, Szadkowska A, Witkowski P, Młynarski W, Jarosz-Chobot P, Bossowski A, Siebert J, Trzonkowski P. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. Clin Immunol. 2014 Jul;153(1):23-30. doi: 10.1016/j.clim.2014.03.016. Epub 2014 Apr 1.</citation>
    <PMID>24704576</PMID>
  </reference>
  <reference>
    <citation>Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, Grabowska M, Techmanska I, Juscinska J, Wujtewicz MA, Witkowski P, Mlynarski W, Balcerska A, Mysliwska J, Trzonkowski P. Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care. 2012 Sep;35(9):1817-20. doi: 10.2337/dc12-0038. Epub 2012 Jun 20.</citation>
    <PMID>22723342</PMID>
  </reference>
  <reference>
    <citation>Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, Maahs DM, Tamborlane WV; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015 Jun;38(6):971-8. doi: 10.2337/dc15-0078.</citation>
    <PMID>25998289</PMID>
  </reference>
  <reference>
    <citation>Monti P, Heninger AK, Bonifacio E. Differentiation, expansion, and homeostasis of autoreactive T cells in type 1 diabetes mellitus. Curr Diab Rep. 2009 Apr;9(2):113-8. Review.</citation>
    <PMID>19323955</PMID>
  </reference>
  <reference>
    <citation>Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, Atkinson MA, Bluestone JA. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes. 2009 Mar;58(3):652-62. doi: 10.2337/db08-1168. Epub 2008 Dec 15.</citation>
    <PMID>19074986</PMID>
  </reference>
  <reference>
    <citation>Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19:225-52. Review.</citation>
    <PMID>11244036</PMID>
  </reference>
  <reference>
    <citation>Sitrin J, Ring A, Garcia KC, Benoist C, Mathis D. Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. J Exp Med. 2013 Jun 3;210(6):1153-65. doi: 10.1084/jem.20122248. Epub 2013 May 6.</citation>
    <PMID>23650440</PMID>
  </reference>
  <reference>
    <citation>Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, Piccirillo CA, Salomon BL, Bluestone JA. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008 May;28(5):687-97. doi: 10.1016/j.immuni.2008.03.016. Epub 2008 May 8.</citation>
    <PMID>18468463</PMID>
  </reference>
  <reference>
    <citation>Tang Q, Bluestone JA. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev. 2006 Aug;212:217-37. Review.</citation>
    <PMID>16903917</PMID>
  </reference>
  <reference>
    <citation>Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008 Mar;9(3):239-44. doi: 10.1038/ni1572. Review.</citation>
    <PMID>18285775</PMID>
  </reference>
  <reference>
    <citation>Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol. 2004 Nov;34(11):2996-3005.</citation>
    <PMID>15468055</PMID>
  </reference>
  <reference>
    <citation>Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, Bluestone JA. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004 Jun 7;199(11):1455-65.</citation>
    <PMID>15184499</PMID>
  </reference>
  <reference>
    <citation>Waldron-Lynch F, Kareclas P, Irons K, Walker NM, Mander A, Wicker LS, Todd JA, Bond S. Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial. BMJ Open. 2014 Jun 4;4(6):e005559. doi: 10.1136/bmjopen-2014-005559.</citation>
    <PMID>24898091</PMID>
  </reference>
  <reference>
    <citation>Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015 Nov 25;7(315):315ra189. doi: 10.1126/scitranslmed.aad4134.</citation>
    <PMID>26606968</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Jeffrey Bluestone</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Treg</keyword>
  <keyword>Proluekin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

